Explainer: a new COVID variant called PJ.2.1 is spreading in several countries abroad. It has not been found in India. The WHO has not flagged it as a variant of concern. Lab tests show current vaccines still work against it. Here is what is known, and what is not.
Updated: 11 November 2026, 10:45 IST
Quick Read
- PJ.2.1 is a new subvariant of the JN.1 family, first sampled in Ontario, Canada, on 2 May 2026. Its share of cases there rose from 1.1% to 25.2% in about three months.
- It has NOT been detected in India, and the WHO has NOT named it a variant of concern, a variant of interest, or a variant under monitoring.
- Lab tests show antibodies from the LP.8.1-adapted vaccine still neutralise it. There is no evidence it causes worse illness, and no distinct symptom list exists for it.
PJ.2.1 is a subvariant of SARS-CoV-2, the virus that causes COVID-19. It comes from the JN.1 family, through an earlier subvariant called MC.10.1.7. The first sample was taken in Ontario, Canada, on 2 May 2026. Scientists call it a “saltation variant”, which means it picked up many mutations at once, instead of one by one. The key study is by Hoffmann and colleagues, published in the Journal of Infection on 24 October 2026.
That is the science. The fear around it is a different matter. Some headlines this week ask if old vaccines will still work. The short answer from the lab data is yes, they still neutralise it. This post sticks to what the study and the WHO actually say, not to the alarm.
Where it has spread, in numbers
Ontario’s genomic surveillance shows how fast PJ.2.1 grew there. Its share of sequenced cases was 1.1% between 28 June and 25 July 2026. Then it rose to 3.5%, then 16.9%, and reached 25.2% between 20 September and 17 October 2026. In plain words, one in four sequenced cases in Ontario in that last period was PJ.2.1.
It has also been found in the United States (first in New York City on 30 June), Spain, France, Israel, Singapore, Australia and New Zealand. Hong Kong reported it in a 5 November update. That is a wide spread, but spread is not the same as danger. A variant can spread fast and still cause the same kind of illness as the ones before it.
Also read: Haj 2027 India quota 175025 guide
What the WHO says — and has not said
The World Health Organization has NOT named PJ.2.1 a variant of concern, a variant of interest, or a variant under monitoring. That matters. The WHO gives those labels when a variant shows signs of being more dangerous or of dodging immunity in a big way. PJ.2.1 has none of those labels.
For scale, JN.1 — the parent family — is listed as a variant of interest. XFG, NB.1.8.1, PQ.16.1.1 and BA.3.2 are listed as variants under monitoring. PJ.2.1 sits below all of them in the WHO’s own list. If the WHO changes that, this post will need an update. As of today, it has not.
Do vaccines still work against it?
Lab tests in the Hoffmann study give the clearest answer so far. Antibodies from the LP.8.1-adapted vaccine still neutralise PJ.2.1. The neutralisation was about 1.8 times lower than against LP.8.1 itself. That is a small drop, not a failure. In lab terms, the vaccine’s antibodies still recognise and block the variant.
Two things are still unknown. First, lab neutralisation is not the same as real-world protection in people — that data does not exist yet for PJ.2.1. Second, there is no evidence that PJ.2.1 causes worse illness, more hospital stays, or more deaths than other variants now in circulation. No study has shown that.
Also read: CBSE datesheet 2027 out: Class 10 12 dates
What about symptoms?
There is no distinct symptom list for PJ.2.1. No source read for this post names symptoms that belong to this variant alone. Anyone who lists “PJ.2.1 symptoms” as a fixed set is guessing. The honest line is that its symptoms, as far as anyone knows, are the same common COVID symptoms — fever, cough, sore throat, tiredness — and nothing in the research marks it out as different.
That is also why this post does not carry a symptom table. A made-up table would be the one thing in this article that could mislead a reader into thinking this variant behaves differently. It does not, on current evidence.
What about India?
PJ.2.1 has NOT been found in India. The country’s genomic surveillance network, INSACOG, watches for new variants through its sequencing labs. Its public dashboard does not list PJ.2.1. That does not prove the variant will never reach India — variants travel with people, and this one is already in several countries. It proves only that it has not been detected here so far.
What should a reader in India do? Nothing new. The same steps that work against every COVID variant still apply: keep vaccinations up to date, stay home when sick, and test if symptoms appear. There is no new rule, no new advisory, and no travel warning tied to PJ.2.1.
Also read: Why Delhi air turns toxic after Diwali
FAQ
Has PJ.2.1 been found in India?
No. There is no confirmed detection in India, and the INSACOG public dashboard does not list it. It has been found in Canada, the US, Spain, France, Israel, Singapore, Australia, New Zealand and Hong Kong.
Has the WHO flagged PJ.2.1 as dangerous?
No. The WHO has not named it a variant of concern, a variant of interest, or a variant under monitoring. Its parent, JN.1, is a variant of interest, but PJ.2.1 itself carries no WHO label.
Do current vaccines work against it?
Lab tests say yes. Antibodies from the LP.8.1-adapted vaccine still neutralise PJ.2.1, about 1.8 times less strongly than against LP.8.1. There is also no evidence it causes more severe illness than other variants in circulation.
Desk-original added context
Our own maths on the Ontario numbers: PJ.2.1’s share of sequenced cases rose from 1.1% to 25.2% — about a 23-fold rise in share — across roughly three months (late June to mid-October 2026). That is fast growth, but it is growth in share, not proof of worse illness. Our own timeline: 2 May 2026 — first sample in Ontario; 30 June — first US detection in New York City; 24 October — Hoffmann study published in the Journal of Infection; 5 November — Hong Kong reports it; 10–11 November — Indian media picks it up, while the WHO still lists no label for it and INSACOG still shows no Indian detection.
Sources
- Moneycontrol — New COVID-19 variant with highly mutated spike protein spreads globally (10 Nov, 200 verified)
- World Health Organization — Tracking SARS-CoV-2 variants (primary: WHO variant labels, 200 verified)
- Open Magazine — New COVID-19 variant PJ.2.1 spreads across countries (6 Nov, 200 verified)
Sasanka Sekhar Pradhan is the founder of India Presents, an India-focused news site. He covers daily box-office trackers, India news, economy explainers, sports previews and festival guides — in simple English, so readers across India can follow fast-moving stories without jargon. His focus is what a story means for the reader: the number that matters, the source behind it, and what happens next. India Presents publishes daily, with day-trackers updated as new figures come in.
